cannabis_print_logoCannabis Science, Inc. is a development-stage company involved in medical marijuana research and development. The company is committed to creating medicines—both with and without psychoactive properties—that are cannabis-based. These medicines aim to treat both the disease and its symptoms, and are also for general health maintenance. Cannabis Science, Inc. is the first and only publicly traded biotech company in the market that is involved in cannabinoid-based extracts, and trades in the OTC market under the symbol CBIS.

To put it simply, the company’s products are medical cannabinoid formulations that stem from at least one of the cannabinoid compounds of the cannabis plant with a primary focus of treating cancer—one of the most important diseases across the globe.

Formerly known as Gulf Onshore, Inc., Cannabis Science is among the oldest companies in the cannabis industry. From the very beginning, its founders have been dedicated to their cause of nurturing and upholding a spirit that encourages innovation from which novel ideas develop and turn into solutions based on evidence.

Thanks to its unique understanding of metabolic processes, the patent-oriented biotech company aims to provide alternative treatment options for individuals with medical needs that are unmet. The company utilizes an inquiring approach in order to discover and develop therapies that can improve patients’ lives.

Cannabis Science continues to create these products with medical cannabinoid formulations as part of its commitment to advocate for the rights of those dealing with life-threatening and debilitating conditions. It works closely with regulatory agencies on local, national, and international levels to ensure the accessibility of their high-quality cannabinoid pharmaceuticals.

Cannabis Science, Inc. works closely with leading experts in clinical research, drug development, and medicinal characterization to develop, create, and commercialize new therapeutic approaches that treat an extensive number of critical ailments such as infections, cancer, and age-related illnesses. All of the materials used in Cannabis Science’s clinical trial are from cultivation and production facilities that are GMP compliant, and that exceed industry standards and food processing requirements.

Yahoo! Finance: CBIS News

Latest Financial News for CBIS

Cannabis Science iCannabinoid Ambassadors Program Appointments Underway; Ambassadors Will Promote Company Initiatives Globally and Help Share Accurate and Reliable Health Information

IRVINE, CA, March 15, 2019 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE -- Cannabis Science, Inc. (CBIS), a U.S. company specializing in the development of cannabinoid-based medicines, announces that today it has launched the selection and appointment process for the Company’s iCannabinoid Ambassador’s Program. One of the most important components of Cannabis Science’s growth and international market penetration strategy is information and the power of the people! The iCannabinoid Ambassador’s Program is expected to help Cannabis Science rapidly expand the Company’s footprint and support the development of new initiatives in new markets. Each iCannabinoid Ambassador will be designated an area of interest and expertise, based on your experience, expertise, and desired level of commitment.

CSE New Listing - Cannabis One Holdings Commences Trading on the Canadian Securities Exchange - Video News Alert on

Vancouver, British Columbia--(Newsfile Corp. - March 1, 2019) -  Cannabis One Holdings (CSE:CBIS) is one of the latest new listing on the Canadian Securities Exchange, having previously traded on the TSX Venture Exchange as Metropolitan Energy Corp., prior to a reverse takeover.For more information, please view the InvestmentPitch Media "video" which provides additional information on the company. If this link is not enabled, please visit and enter "Cannabis One" in the search box.Cannot ...

IIROC Trade Resumption - CBIS

IIROC Trade Resumption - CBIS

IIROC Trading Halt - CBIS

IIROC Trading Halt - CBIS

Cannabis Science Set to Integrate Its Sponsored Research In Nigeria to Include Its U.S. Patent Number 9,763,991 for Compositions of Cannabinol (CBN) for Treatment of Various Neurological Conditions

IRVINE, CA, Feb. 25, 2019 -- Pre-Clinical Work and Animal Studies Underway, and Protocols for Clinical Studies Under Development   via NEWMEDIAWIRE -- Cannabis Science,.